What You Should Know:
– Complement 1, a health technology startup pioneering personalized lifestyle medicine for cancer care, has announced a $16 million oversubscribed seed funding round led by Owl Ventures and Blume Ventures.
– Emerging from stealth, the company is launching the first tech-enabled, clinically validated lifestyle modification platform for cancer patients and high-risk individuals. The platform delivers daily, personalized guidance through one-on-one support from dedicated CoActive Coaches.
Complement 1 Raises $16M to Scale Evidence-Based Lifestyle Medicine Platform for Cancer Care
Founded in 2024, Complement 1 is a U.S.-based health technology company transforming oncology care through clinically validated, tech-enabled lifestyle medicine. Its flagship platform offers personalized, daily one-on-one CoActive Coaching for cancer patients, survivors, and individuals at high risk—supporting them in adopting and sustaining evidence-based interventions across physical activity, nutrition, and somatic practices.
Built on extensive meta-analyses and clinical trials, the platform delivers measurable health benefits while integrating seamlessly with conventional oncology care. Outcomes among Complement 1 users have included 37% fewer treatment side effects, 18% less pain, 27% improved sleep, and program adherence rates exceeding 90%. At the same time, the platform supports healthcare systems by reducing cancer-related costs by up to 30%.
To deliver this impact, Complement 1 uses a medically validated rule engine to tailor interventions to each individual’s cancer type, treatment stage, side-effect profile, and personal preferences. Programs are aligned with leading oncology guidelines, including those from the American Institute for Cancer Research, ensuring relevance and clinical rigor. All care is delivered by dedicated CoActive Coaches, who provide daily, high-touch support to drive long-term behavior change.
With nearly 1 in 2 Americans expected to receive a cancer diagnosis in their lifetime, the need for scalable, integrative care models is urgent. Decades of research have demonstrated that targeted changes in diet, physical activity, stress management, and related behaviors can reduce recurrence by 35% and mortality by 37%, while significantly improving quality of life. Yet despite this evidence, lifestyle medicine remains underutilized in cancer care. Complement 1 aims to close this gap by making personalized behavioral support an integral part of oncology treatment pathways.
To accelerate its impact, the company recently announced a $16 million oversubscribed seed funding round led by Owl Ventures and Blume Ventures, with participation from prominent healthcare-focused angel investors. This funding will enable Complement 1 to:
- Scale its CoActive Coaching operations and infrastructure across the United States
- Advance its AI-driven personalization engine for more precise, adaptive programming
- Deepen partnerships with cancer centers, health plans, and employers
- Invest in digital product development to enhance user experience for both patients and coaches
Early actuarial modeling suggests that the company’s approach could reduce healthcare costs across cancer and high-risk populations by 30% through scalable lifestyle adherence.
As Karan Bajaj, CEO and Co-Founder, noted, “Every oncologist understands the value of lifestyle change in improving patient outcomes, but implementation has remained a challenge. Complement 1 addresses this gap through high-tech, high-touch coaching that patients can realistically engage with throughout their treatment journey.”
With clinical validation, strong patient engagement, and investor backing, Complement 1 is positioned to redefine cancer care delivery—empowering patients to take control of their health through holistic, evidence-based lifestyle interventions.
